{"entity":{"id":"nanobiotix","kind":"company","name":"Nanobiotix","aka":[],"tldr":"Nanobiotix is the Paris nanomedicine company behind NBTXR3, hafnium oxide nanoparticles injected into a tumour to make radiotherapy deposit more energy inside it.","summary":"Founded in 2003 and listed on Euronext Paris and Nasdaq, Nanobiotix built its business on the physics of radioenhancement: high atomic number nanoparticles that absorb X-rays and amplify the dose within the tumour. Its lead product NBTXR3 received a European CE mark for soft-tissue sarcoma in 2019 and is in the NANORAY-312 phase 3 trial in head and neck cancer, licensed to Johnson and Johnson in 2023.","asOf":"2026-09-16","links":[{"label":"Official website","url":"https://www.nanobiotix.com"}],"tags":["radiation-wave3","radiation"],"related":[],"cancers":["sarcoma","head-and-neck"],"sections":[],"technologies":["radiosensitisers"],"targets":[],"drugs":["nbtxr3"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"hq":"Paris, France","country":"FR","companyType":"biotech","website":"https://www.nanobiotix.com","founded":2003,"stage":"public","investors":[],"funding":[]},"route":"/companies/nanobiotix/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"technology":[{"id":"radiosensitisers","kind":"technology","name":"Radiosensitisers","route":"/technologies/radiosensitisers/"}],"drug":[{"id":"nbtxr3","kind":"drug","name":"NBTXR3 (hafnium oxide nanoparticles)","route":"/drugs/nbtxr3/"}]}}